In an article titled “Recognizing the need for personalization of hemophilia patient-reported outcomes in the prophylaxis era” published in the scientific journal Haemophilia, researchers reviewed two new tools that are used to measure patient reported outcome measures.
Search results for:
Aging can affect mobility and lead to a series of complications for people with hemophilia, including increasing the risk of joint bleeds and irreversible joint damage. Regular exercise and physical therapy can be an important part of maintaining your strength, protecting your joints, and managing hemophilia’s impact on…
Hemophilia treatment can be costly, but understanding insurance options and financial assistance programs may help reduce the burden. This resource highlights key costs and support tools to help you better manage care expenses.
Connecting with others affected by hemophilia B can help you find a community with whom you can share what it’s like living with hemophilia B, including talking about daily life, symptoms, and treatments.
World Hemophilia Day is today, April 17, and this year’s chosen theme by the World Federation for Hemophilia (WFH) is “Equitable access for all: recognizing all bleeding disorders.” On its website, the WFH called for moving toward “a world where all people with inherited bleeding disorders have…
Understanding hemophilia treatment options if you have inhibitors
Fact-Checked By Lindsey Shapiro, PhD
Hemophilia inhibitors can reduce treatment effectiveness and raise bleeding risks, but several therapies can help maintain control. Understanding your options can support more confident, informed care decisions.
Hemophilia can affect everyone differently, depending on your symptoms, the type of hemophilia you have, and its severity. This is why your care team should be based on your individual needs. But regardless of the specific specialists, you want a coordinated, comprehensive, multidisciplinary team of healthcare professionals…
The severity levels of hemophilia are determined by the level of residual/remaining clotting factor (factor VIII or factor IX) activity in the patient’s blood, which is denoted by the percentage of factor activity in the blood (or international units per ml of blood – IU/ml). According to the World Federation of Hemophilia,…